Published in Exp Parasitol on January 25, 2011
A quinoxaline derivative as a potent chemotherapeutic agent, alone or in combination with benznidazole, against Trypanosoma cruzi. PLoS One (2014) 0.86
Quinoxaline 1,4-di-N-Oxides: Biological Activities and Mechanisms of Actions. Front Pharmacol (2016) 0.82
In Vitro and In Vivo Activities of 2,3-Diarylsubstituted Quinoxaline Derivatives against Leishmania amazonensis. Antimicrob Agents Chemother (2016) 0.79
Anti-Trypanosoma cruzi and anti-leishmanial activity by quinoxaline-7-carboxylate 1,4-di-N-oxide derivatives. Parasitol Res (2014) 0.78
Multiple norovirus infections in a birth cohort in a Peruvian Periurban community. Clin Infect Dis (2013) 2.37
Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis. J Infect Dis (2007) 2.33
Synthesis and antimycobacterial activity of new quinoxaline-2-carboxamide 1,4-di-N-oxide derivatives. Bioorg Med Chem (2003) 1.61
Thyroid hormone levels improve the prediction of mortality among patients admitted to the intensive care unit. Intensive Care Med (2005) 1.55
A call for using natural compounds in the development of new antimalarial treatments - an introduction. Malar J (2011) 1.14
Evaluation of molecular tools for detection and drug susceptibility testing of Mycobacterium tuberculosis in stool specimens from patients with pulmonary tuberculosis. J Clin Microbiol (2010) 1.11
Synthesis and anticancer activity evaluation of new 2-alkylcarbonyl and 2-benzoyl-3-trifluoromethyl-quinoxaline 1,4-di-N-oxide derivatives. Bioorg Med Chem (2004) 1.10
Synthesis, cytotoxicity, and anti-Trypanosoma cruzi activity of new chalcones. J Med Chem (2008) 1.06
Diagnosis of pediatric pulmonary tuberculosis by stool PCR. Am J Trop Med Hyg (2008) 1.06
Synthesis and biological evaluation of new 2-arylcarbonyl-3-trifluoromethylquinoxaline 1,4-di-N-oxide derivatives and their reduced analogues. J Med Chem (2007) 1.06
[Strengthening global health informatics research within the andean region through international collaboration]. Rev Peru Med Exp Salud Publica (2010) 1.05
Synthesis of new quinoxaline-2-carboxylate 1,4-dioxide derivatives as anti-Mycobacterium tuberculosis agents. J Med Chem (2005) 1.02
SYBR Green-based quantitation of human T-lymphotropic virus type 1 proviral load in Peruvian patients with neurological disease and asymptomatic carriers: influence of clinical status, sex, and familial relatedness. J Neurovirol (2006) 1.00
Genetic diversity of Mycobacterium tuberculosis in Peru and exploration of phylogenetic associations with drug resistance. PLoS One (2013) 0.98
New copper-based complexes with quinoxaline N1,N4-dioxide derivatives, potential antitumoral agents. J Inorg Biochem (2007) 0.97
Medicinal plants from the Yanesha (Peru): evaluation of the leishmanicidal and antimalarial activity of selected extracts. J Ethnopharmacol (2009) 0.94
Campylobacter transmission in a Peruvian shantytown: a longitudinal study using strain typing of campylobacter isolates from chickens and humans in household clusters. J Infect Dis (2003) 0.94
Peruvian and globally reported amino acid substitutions on the Mycobacterium tuberculosis pyrazinamidase suggest a conserved pattern of mutations associated to pyrazinamide resistance. Infect Genet Evol (2009) 0.93
DNA-level diversity and relatedness of Helicobacter pylori strains in shantytown families in Peru and transmission in a developing-country setting. J Clin Microbiol (2008) 0.93
[Prevalence of entero-parasitosis in one Andean community in the Province of Victor Fajardo, Ayacucho, Peru]. Rev Gastroenterol Peru (2005) 0.91
Selective activity against Mycobacteriumtuberculosis of new quinoxaline 1,4-di-N-oxides. Bioorg Med Chem (2008) 0.91
Efficacy of quinoxaline-2-carboxylate 1,4-di-N-oxide derivatives in experimental tuberculosis. Antimicrob Agents Chemother (2008) 0.91
pncA gene expression and prediction factors on pyrazinamide resistance in Mycobacterium tuberculosis. Tuberculosis (Edinb) (2013) 0.90
Synthetic chalcones, flavanones, and flavones as antitumoral agents: biological evaluation and structure-activity relationships. Bioorg Med Chem (2007) 0.90
In vitro and in vivo anti-Leishmania activity of polysubstituted synthetic chalcones. Bioorg Med Chem Lett (2009) 0.90
High degree of Plasmodium vivax diversity in the Peruvian Amazon demonstrated by tandem repeat polymorphism analysis. Am J Trop Med Hyg (2012) 0.89
In vitro and in vivo antimycobacterial activities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxide. J Antimicrob Chemother (2008) 0.89
Aryl piperazine and pyrrolidine as antimalarial agents. Synthesis and investigation of structure-activity relationships. Exp Parasitol (2011) 0.86
Prediction score for antimony treatment failure in patients with ulcerative leishmaniasis lesions. PLoS Negl Trop Dis (2012) 0.86
Structure-Activity relationship in mutated pyrazinamidases from Mycobacterium tuberculosis. Bioinformation (2011) 0.86
An intervention-control study of corralling of free-ranging chickens to control Campylobacter infections among children in a Peruvian periurban shantytown. Am J Trop Med Hyg (2006) 0.86
Synthesis of new 2-acetyl and 2-benzoyl quinoxaline 1,4-di-N-oxide derivatives as anti-Mycobacterium tuberculosis agents. Eur J Med Chem (2003) 0.86
Variation of leishmanicidal activity in four populations of Urechites andrieuxii. J Ethnopharmacol (2003) 0.85
Biological activities of nitidine, a potential anti-malarial lead compound. Malar J (2012) 0.84
Synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates. Bioorg Med Chem (2008) 0.84
DNA strand cleaving properties and hypoxia-selective cytotoxicity of 7-chloro-2-thienylcarbonyl-3-trifluoromethylquinoxaline 1,4-dioxide. Bioorg Med Chem (2010) 0.84
Synthesis and antimycobacterial activity of new quinoxaline-2-carboxamide 1,4-di-N-oxide derivatives. Eur J Med Chem (2010) 0.84
Cytotoxic, mutagenic and genotoxic effects of new anti-T. cruzi 5-phenylethenylbenzofuroxans. Contribution of phase I metabolites on the mutagenicity induction. Toxicol Lett (2009) 0.84
Evaluation of bleach-sedimentation for sterilising and concentrating Mycobacterium tuberculosis in sputum specimens. BMC Infect Dis (2011) 0.84
Cytotoxic and anti-infective sesquiterpenes present in Plagiochila disticha (Plagiochilaceae) and Ambrosia peruviana (Asteraceae). Planta Med (2009) 0.84
Phenazine 5,10-dioxide derivatives as hypoxic selective cytotoxins. J Med Chem (2005) 0.83
New therapeutic targets for drug design against Trypanosoma cruzi, advances and perspectives. Curr Med Chem (2009) 0.83
Antidepressant-like activity of VN2222, a serotonin reuptake inhibitor with high affinity at 5-HT1A receptors. Eur J Pharmacol (2002) 0.83
Synthesis and molecular modeling of new 1-aryl-3-[4-arylpiperazin-1-yl]-1-propane derivatives with high affinity at the serotonin transporter and at 5-HT(1A) receptors. J Med Chem (2002) 0.83
Synthesis and anti-inflammatory/antioxidant activities of some new ring substituted 3-phenyl-1-(1,4-di-N-oxide quinoxalin-2-yl)-2-propen-1-one derivatives and of their 4,5-dihydro-(1H)-pyrazole analogues. Bioorg Med Chem Lett (2007) 0.83
Pyrazolo[3,4-b]quinoxalines. A new class of cyclin-dependent kinases inhibitors. Bioorg Med Chem (2002) 0.83
Docking and quantitative structure-activity relationship studies for 3-fluoro-4-(pyrrolo[2,1-f][1,2,4]triazin-4-yloxy)aniline, 3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)aniline, and 4-(4-amino-2-fluorophenoxy)-2-pyridinylamine derivatives as c-Met kinase inhibitors. J Comput Aided Mol Des (2011) 0.82
Outside-binding site mutations modify the active site's shapes in neuraminidase from influenza A H1N1. Biopolymers (2013) 0.82
Anti-Mycobacterium tuberculosis agents derived from quinoxaline-2-carbonitrile and quinoxaline-2-carbonitrile 1,4-di-N-oxide. Arzneimittelforschung (2002) 0.82
Indazole N-oxide derivatives as antiprotozoal agents: synthesis, biological evaluation and mechanism of action studies. Bioorg Med Chem (2006) 0.82
3-Trifluoromethylquinoxaline N,N'-dioxides as anti-trypanosomatid agents. Identification of optimal anti-T. cruzi agents and mechanism of action studies. J Med Chem (2011) 0.81
Quinoxaline N,N'-dioxide derivatives and related compounds as growth inhibitors of Trypanosoma cruzi. Structure-activity relationships. Bioorg Med Chem Lett (2004) 0.81
Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway. Oncotarget (2012) 0.81
New 3-methylquinoxaline-2-carboxamide 1,4-di-N-oxide derivatives as anti-Mycobacterium tuberculosis agents. Bioorg Med Chem (2010) 0.81
Curcuma as a parasiticidal agent: a review. Planta Med (2010) 0.81
Genome sequence and comparative analysis of Avibacterium paragallinarum. Bioinformation (2013) 0.81